| Bioactivity | K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity[1]. |
| Invitro | K145 (0-10 µM; 24-72 hours; U937 cells) treatment significantly inhibits the growth of U937 cells in a concentration-dependent manner[1].K145 (10 µM; 24 hours; U937 cells) treatment significantly induces apoptosis in U937 cells[1].K145 (4-8 µM; 3 hours; U937 cells) treatment decreases the phosphorylation of ERK and Akt[1].Treatment with K145 (10 µM) causes a decrease of total cellular S1P without significant effects on ceramide levels[1]. Cell Viability Assay[1] Cell Line: |
| Name | K145 |
| CAS | 1309444-75-4 |
| Formula | C18H24N2O3S |
| Molar Mass | 348.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |